Overview

Developing Innovative Therapeutic Solutions for Established Treatment Paradigms in Mature Markets to Significantly Improve Patient Outcomes and Create Long-Term Revenue Opportunities

We believe that the leaders in medtech innovation have a major opportunity to improve the development of promising therapeutic solutions by adapting proven effective strategies used widely by biopharma companies.

Traditionally, the biopharma model supports partnership or licensing opportunities before commercialization based on assessments of forward value and long-term revenue potential. By forging strategic relationships with global commercial partners at the development stage, biopharma companies are able to access the capital necessary to fuel innovation and build high-impact, multi-asset pipelines that offer diversified opportunities for their stakeholders.

Orchestra BioMed’s unique vision of adapting proven biopharma strategies to therapeutic products that are traditionally considered medical devices has led to development of a diversified pipeline of late-stage assets with lead indications in large, mature markets with established treatment paradigms including hypertension and artery disease:

  • Virtue® Sirolimus-Eluting Balloon (SEB) (originally developed by Caliber Therapeutics, a wholly-owned subsidiary of Orchestra BioMed) is a novel, first-in-class device that delivers delayed-release bioabsorbable particle encapsulated sirolimus, the proven gold standard drug for preventing restenosis of treated arteries, to the vessel wall during balloon angioplasty without the need for a permanent implant.

  • BackBeat Cardiac Neuromodulation Therapy (CNT) (originally developed by BackBeat Medical, a wholly-owned subsidiary of Orchestra BioMed) is a patented implantable cardiac stimulation-based treatment for hypertension that immediately and substantially lowers blood pressure while simultaneously modulating autonomic nervous system responses that normally drive and maintain blood pressure higher.

Orchestra BioMed Diagram

Orchestra BioMed also has significant strategic ownership in additional commercial assets through one wholly-owned subsidiary (FreeHold Surgical®) and large minority interests in two other therapeutic device companies (Motus GI®, Vivasure® Medical), all of which were founded or financed and developed with the assistance of the principals of Orchestra BioMed.

Freehold Surgical
Vivasure Medical
Motus GI
Have any questions?
Contact us at 917.254.4900 or info@orchestrabiomed.com